6[2]DOJO M,AZUMA T,SAITO T,et al.Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole),amoxycillin and clarithromycin in Japan[J].Dig Liver Dis,2001,33(8):671 -675.
7[3]SAGAR M,TYBRING G,DAHL M L,et al.Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism[J].Gastroenterology,2000,119(3):670-676.
8[5]FURUTA T,SAGEHASHI Y,SHIRAI N,et al.Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection[J].Clin Gastroenterol Hepatol,2005,3(6):564-573.
9[6]TOGAWA J,INAMORI M,FUJISAWA N,et al.Efficccy of a triple therapy with rabeprazole,amoxicillin,and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy[J].Hepatogastroenterology,2005,52 (62):645-648.
10[7]SAITO M,YASUI-FURUKORI N,UNO T,et al.Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes[J].Br J Clin Pharmacol,2005,59(3):302-309.
